Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

The VanEck Pharmaceutical ETF (PPH) screens as the more cost-and-income efficient option, with a 0.36% expense ratio vs 0.57% for Invesco (PJP) and a higher dividend yield (2.00% vs 0.90%), though its 1-year total return lagged (27.1% for PPH vs 49.9% for PJP). Over 5 years, PPH shows stronger growth of $1,632 vs $1,530 for PJP, despite slightly worse max drawdown (20.3% vs 17.5%). The key tradeoff highlighted is PPH’s more concentrated top holdings (largest position >20% of AUM) and more global exposure (62% U.S.) versus PJP’s broader U.S.-only exposure (29 holdings).

Analysis

The real signal here is not “pharma is attractive,” but that ETF wrapper choice is creating two very different factor exposures. PPH is effectively a concentrated LLY/NVS/MRK vehicle with a lower fee and better income profile, so its return path will be dominated by one or two underlying names; that makes it a higher-conviction expression of the GLP-1 / large-cap pharma theme, but also much more fragile if LLY disappoints. PJP is the broader U.S. basket and should be less sensitive to a single-stock drawdown, which matters if the market starts rotating away from crowded momentum into more diffuse defensive exposure.

Second-order flow effects matter more than the headline comparison. If allocators migrate to PPH for yield, the incremental demand still mostly lands in LLY because of the weight structure, so the ETF can become a levered flow amplifier for that name rather than a true diversifier. The hidden risk is currency and withholding-tax drag on the non-U.S. sleeve: in a strong-dollar regime, PPH can underperform even if the underlying pharma complex is stable.

The contrarian view is that the “cheaper/higher-yield” pitch may be too slow-moving to beat factor momentum over the next 1-3 months. If LLY keeps trending on obesity data or pricing power, PJP may continue to win despite the fee gap because its lighter concentration dilutes single-name volatility. Falsifiers: a sharp LLY correction, a broad rotation into income/defensive equities, or a renewed regulatory scare around drug pricing that compresses the whole complex.

Key Decisions for Investors

• Long PPH / short PJP in equal dollars for 3-6 months if the objective is relative-value income + lower-fee exposure; target 3-5% spread outperformance, stop if LLY breaks to new highs on materially improving GLP-1 sentiment.
• If you want pure exposure to the dominant pharma factor, prefer LLY over either ETF; PPH is a levered wrapper around LLY risk, so use the stock directly when the thesis is single-name momentum rather than sector allocation.
• Avoid overpaying for PJP momentum unless you explicitly want a U.S.-only basket; the fee/yield handicap is small, but its recent outperformance is vulnerable if the market rotates from growth to defensive income within 1-3 months.
• Watch the dollar: a stronger USD is a relative tailwind for PJP vs PPH over 6-12 months because PPH’s international sleeve introduces currency drag and potential withholding-tax leakage.